Table 2. Meta-analysis results for chromosome 6 SNP associations to peak creatinine during vancomycin therapy.

			Primary Cohort (N = 489)			Marshfield Validation (N = 343)		Mayo Validation (N = 59)		VGER Validation (N = 37)		Meta-Analysis (Primary + Validation)
SNP	Position	Risk Allele	RAF	β (SE)	P	β (SE)	P	β (SE)	P	β (SE)	P	β (SE)	Meta-P
rs2789047	121231501	A	0.28	-0.06 (0.01)	1.1x10-7	-0.02 (0.04)	0.57	-0.001 (0.07)	0.99	0.09 (0.37)	0.81	-0.05 (0.01)	1.1x10-7
rs12527161	121236583	T	0.27	-0.06 (0.01)	1.8x10-7	-0.02 (0.04)	0.63	-0.02 (0.07)	0.76	0.09 (0.37)	0.81	-0.05 (0.01)	1.8x10-7
rs9320773	121218196	A	0.27	-0.06 (0.01)	2.0x10-7	-0.01 (0.04)	0.82	-0.04 (0.08)	0.62	0.001 (0.34)	1.0	-0.05 (0.01)	2.3x10-7
rs1886249	121791852	c	0.14	-0.02 (0.01)	0.13	-0.04 (0.04)	0.35	-0.03 (0.08)	0.74	0.30 (0.43)	0.50	-0.023 (0.01)	0.081
rs3805787	121800606	c	0.23	-0.01 (0.01)	0.43	-0.03 (0.04)	0.37	-0.04 (0.07)	0.59	0.26 (0.46)	0.58	-0.012 (0.01)	0.28
rs17083553*	121775368	T	0.19	0.01 (0.01)	0.65	0.07 (0.05)	0.12	0.01 (0.07)	0.99	-0.37 (0.44)	0.41	0.009 (0.01)	0.413
rs6932373*	121832689	A	0.38	0.002 (0.01)	0.87	-0.04 (0.03)	0.27	-0.09 (0.07)	0.19	0.08 (0.23)	0.74	-0.003 (0.01)	0.752
rs2389541	121815698	c	0.31	0.01 (0.01)	0.31	-0.07 (0.04)	0.05	-0.09 (0.07)	0.20	0.10 (0.26)	0.70	0.002 (0.01)	0.805
rs17083598	121788169	g	0.06	0.01 (0.02)	0.75	-0.09 (0.06)	0.18	-0.08 (0.16)	0.62	1.01 (0.63)	0.12	-0.002 (0.02)	0.902

RAF—Risk Allele Frequency; SE—Standard Error.

*—Imputed SNP in Mayo and VGER cohorts.